Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly (LLY) shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro. The drugmaker said it ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

Eli Lilly unexpectedly lowered ... Meanwhile, its non-weight loss drug portfolio is also growing nicely. From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E) of 25.4 ...

Eli Lilly's GLP-1 market dominance, supported by superior efficacy and strong manufacturing investments, positions it as a leader alongside Novo Nordisk, with forecasted revenue growth to $75B by ...